Antibodies, chemical reagents and shRNAs
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The following antibodies were used: α/β-Tubulin (2148), AKT (9272), Two small hairpin RNAs (shRs) were used to target SHP2, SHP2 shR1 9 starting at the nucleotide 879 (5'-GTGACCCATGTTATGATTCGC-3'), 10 which targets the consensus coding DNA sequence (CCDS) region, and 11 SHP2 shR2 starting at the nucleotide 6060 (5'-CCACGTATATTAT 12 GTAGTCTA-3'), which targets the 3' untranslated region. CD19 13 targeting shR was started at the nucleotide 984 (5'-GTGGGCATTCTTC-14 ATCTTCAA-3') and c-Myc targeting shR was started at the nucleotide 15 560 (5'-CTCCCGCGACGATGCCCCTCA-3'). All these shRs were 16 sequence-confirmed and cloned into the pLL3.7-GFP vector (Clontech). 17 Rescue experiments were performed with pLV-YFP vector (Addgene) 18 expressing wild type SHP2, CD19 and c-Myc. BAY 11-7082, Dasatinib 19 and LY294002 were purchased from Sigma. PD0325901 and U0126 were 20 purchased from Selleck. (Table S6) independently scored in the TMA, each using a 10-tiered scale (0-9). The 20 result of both was used as a case score and a value of 10 or greater was 21 considered positive for χ² calculations. The phospho-Tyr542-SHP2 (Table S7 ). The phospho-Tyr531-CD19 2 positive cases were divided as: moderate = score 10-39, strong = score 40 3 and above. The phospho-Thr202/Tyr204-ERK1/2 cases were divided as: 4 moderate = score 10-20, strong = score 21 and above. Biosystems). GAPDH was used as loading control. All the primers were 14 designed to specifically amplify human transcripts (Table S4) . Tables   Table S1 . prime sequences used for real time PCR.
Gene name Forward primer sequence Reverse primer sequence P values for the down-regulation of each individual GC lymphoma proliferative signature shown in Fig. S2A ,B are listed. Numbers at the bottom indicate the overall proportion of down-regulated genes (p < 0.05) by each inhibitor treatment. P values for the down-regulation of each individual GC lymphoma proliferative signature shown in Fig. S2A ,B are listed. Numbers at the bottom indicate the overall proportion of down-regulated genes (p < 0.05) by each inhibitor treatment. Patient phosphor-SHP2 Phosphor-ERK1/2 phosphor-CD19 BCL2 BCL6 CD10 CD20 MUM1 EBER IGH/MYC translocation 
